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Need for advocacy for maternal 
immunisation
To the Editor: Even in the current era, many vaccine-preventable 
diseases, such as measles, polio and hepatitis B, still constitute a 
significant public health burden despite effective vaccines being 
available. Various factors contribute to reduced vaccine coverage, 
such as war-ravaged countries, rural areas with lack of access to 
healthcare, and the anti-vaxxers, who refuse vaccination, stemming 
from the disproved measles, mumps, rubella vaccine claims. This 
leads to disease outbreaks with considerable morbidity and mortality, 
e.g. measles outbreaks in developing and developed countries.
Besides the advocacy needed for childhood immunisation of 
vaccine-preventable diseases worldwide, there also exists a need 
for advocacy with regard to maternal immunisation that healthcare 
professionals and the public are not well aware of. Maternal 
immunisation – vaccination of pregnant women – has been shown 
in trials to protect both the mother and her infant from many 
vaccine-preventable diseases.[1,2] Transplacental transfer of maternal 
IgG antibodies provides passive immunity to the infant in the first 
6 months of life.[3] As a pregnant healthcare professional seeking 
vaccination, I was surprised to discover that many obstetricians are 
unaware of the benefits of maternal immunisation and do not make 
any recommendations to their pregnant patients. 
The South African (SA) National Institute for Communicable 
Diseases recommends inactivated influenza vaccine for all pregnant 
women at any stage of pregnancy during the influenza season.[4] 
Pregnant women are at increased risk of severe or complicated influ-
enza and adverse birth outcomes.[4] A randomised placebo-controlled 
trial in SA found the influenza vaccine to be safe and effective in 
both HIV-infected and HIV-uninfected women and their infants.[5] 
The influenza vaccine is not licensed for infants <6 months of age 
who are vulnerable to severe or complicated influenza.[4] Maternal 
influenza immunisation has been shown to protect infants for the 
first 6 months of life.[5]
Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination 
of pregnant women has been implemented in the UK and the USA 
since 2012.[3] Pertussis outbreaks in the USA resulted from the lower 
duration of protection from the acellular v. the previous whole-cell 
pertussis vaccines.[6] Locally, in KwaZulu-Natal, there were diphtheria 
outbreaks, and pertussis cases occur nationally.[7,8] The need therefore 
exists in our setting to protect infants before they develop immunity 
from the infant vaccine series.
Vaccines in development for maternal immunisation are for the 
respiratory syncytial virus, which causes bronchiolitis and pneu-
monia and is a major cause of morbidity and mortality in children, 
especially infants, and for group B streptococcus, which is a leading 
cause of invasive infection within the first 3 months of life.[9,10]
There is a misconception among the general public that all vaccines 
are unsafe during pregnancy; education by healthcare professionals 
and media communications to dispel false beliefs are required. With 
the influenza season on the horizon, I urge healthcare professionals to 
recommend maternal influenza vaccination. Maternal immunisation 
has the potential to improve maternal and infant health outcomes.
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